Yi-Yu Ke
Overview
Explore the profile of Yi-Yu Ke including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
472
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fan C, Hung H, Chen C, Chen L, Ke Y, Yeh T, et al.
Cells
. 2024 Jul;
13(13.
PMID: 38994997
Extracellular HSP90α (eHSP90α) is a promoter of tumor development and malignant progression. Patients with malignancies, including pancreatic ductal adenocarcinoma (PDAC), have generally shown 5~10-fold increases in serum/plasma eHSP90α levels. In...
2.
Chang C, Yeh T, Chen C, Wang W, Chen Y, Tsai C, et al.
Mol Cancer Ther
. 2024 Apr;
23(6):766-779.
PMID: 38592383
Aurora kinase inhibitors, such as alisertib, can destabilize MYC-family oncoproteins and have demonstrated compelling antitumor efficacy. In this study, we report 6K465, a novel pyrimidine-based Aurora A inhibitor, that reduces...
3.
Yao C, Shen Z, Rajan Y, Huang Y, Lin C, Song J, et al.
Eur J Med Chem
. 2023 Jul;
258:115583.
PMID: 37393792
Down-regulation of Cisd2 in the liver has been implicated in the development of nonalcoholic fatty liver disease (NAFLD) and increasing the level of Cisd2 is therefore a potential therapeutic approach...
4.
Kuppusamy R, Hsu Y, Ke Y, Chang P, Chang Y, Chang H, et al.
Eur J Med Chem
. 2022 Sep;
243:114728.
PMID: 36084534
Currently, there is a significant unmet need for novel analgesics with fewer side effects. In this study, we carried out structural modification of a hit compound previously identified in an...
5.
Lin S, Tien Y, Ke Y, Chang Y, Chang H, Ou L, et al.
Bioorg Chem
. 2022 Jun;
128:105905.
PMID: 35710525
We identified, via high-throughput screening using a FLIPR® calcium assay, compound 1, which incorporated a dihydroquinolinyl-2-oxoethylsulfanyl-(1H,5H)-pyrimidinedione core and activated the μ-opioid receptor (MOR) in the presence of naloxone or naltrexone....
6.
Fang M, Huang K, Tu W, Chen Y, Pan P, Hsiao W, et al.
Redox Biol
. 2021 Sep;
46:102126.
PMID: 34509914
Nitro-fatty acids are a class of endogenous electrophilic lipid mediators with anti-inflammatory and cytoprotective effects in a wide range of inflammatory and fibrotic disease models. While these beneficial biological effects...
7.
Chueh J, Peng K, Wu V, Wang S, Chan C, Chen Y, et al.
J Mol Endocrinol
. 2021 Aug;
67(4):203-215.
PMID: 34463641
Somatic mutation in the KCNJ5 gene is a common driver of autonomous aldosterone overproduction in aldosterone-producing adenomas (APA). KCNJ5 mutations contribute to a loss of potassium selectivity, and an inward...
8.
Chi Y, Yeh T, Ke Y, Lin W, Tsai C, Wang W, et al.
J Med Chem
. 2021 May;
64(11):7312-7330.
PMID: 34009981
The A-type Aurora kinase is upregulated in many human cancers, and it stabilizes MYC-family oncoproteins, which have long been considered an undruggable target. Here, we describe the design and synthesis...
9.
Song J, Chang C, Wu C, Dinh T, Jan J, Huang K, et al.
Proc Natl Acad Sci U S A
. 2021 Mar;
118(13).
PMID: 33753481
The CXC chemokine receptor type 4 (CXCR4) receptor and its ligand, CXCL12, are overexpressed in various cancers and mediate tumor progression and hypoxia-mediated resistance to cancer therapy. While CXCR4 antagonists...
10.
Tsou L, Yeh S, Ueng S, Chang C, Song J, Wu M, et al.
Sci Rep
. 2020 Oct;
10(1):16771.
PMID: 33033310
Machine learning is a well-known approach for virtual screening. Recently, deep learning, a machine learning algorithm in artificial neural networks, has been applied to the advancement of precision medicine and...